Company: BDRX
Filing Date: 2025-11-17
Form Type: F-1
Source: 0001214659-25-016821
Chunk: 26

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-11-17
Form: F-1
Chunk 26
---
 or sale of any specific number or dollar amount of the securities. There is no
required minimum number of securities that must be sold as a condition to completion of this offering. Because there is no minimum offering
amount required as a condition to the closing of this offering, the actual offering amount, Placement Agent fees and proceeds to us are
not presently determinable and may be substantially less than the maximum amounts set forth above. We may sell fewer than all of the securities
offered hereby, which may significantly reduce the amount of proceeds received by us, and investors in this offering will not receive
a refund in the event that we do not sell an amount of securities sufficient to support our continued operations, including our near-term
continued operations. Thus, we may not raise the amount of capital we believe is required for our operations in the short-term and may
need to raise additional funds, which may not be available or available on terms acceptable to us.

This offering may result in an immediate trading halt or delisting of our Depositary Shares from NASDAQ due to public interest concerns.

Under NASDAQ Listing
Rule 5101, NASDAQ has broad discretionary authority to terminate the listing of securities, subject to a timely-requested hearing, if
it determines that continued listing is not in the public interest, even if the issuer is in compliance with NASDAQ’s enumerated
listing criteria. The Series L Warrants contain exercise price reset and share combination event provisions that may result in a downward
adjustment to the exercise price, subject to a floor price, and a corresponding increase in the number of Depositary Shares issuable upon
exercise therefor, such that the aggregate exercise price would remain unchanged. As a result of such features, the number of Depositary
Shares issuable upon exercise of the Series L Warrants may increase significantly. If NASDAQ determines the terms of this offering raise
public interest concerns due to the dilutive nature of the transaction, or any other reason, NASDAQ may issue a determination letter to
delist our Depositary Shares pursuant to its discretionary authority under NASDAQ Listing Rule 5101. In that event, even if we were to
timely request a hearing with respect to NASDAQ’s determination to delist our Depositary Shares, NASDAQ may still impose an immediate
halt on the trading of our Depositary Shares pursuant to NASDAQ Listing Rule 4120(a)(5) pending the outcome of such hearing. If trading
in our Depositary Shares were to be halted or if NASDAQ were